The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio
Open accessAbstract
The amyloid peptides Aβ(40) and Aβ(42) of Alzheimer's disease are thought to contribute differentially to the disease process. Although Aβ(42) seems more pathogenic than Aβ(40), the reason for this is not well understood. We show here that small alterations in the Aβ(42):Aβ(40) ratio dramatically affect the biophysical and biological properties of the Aβ mixtures reflected in their aggregation kinetics, the morphology of the resulting amyloid fibrils and synaptic function tested in vitro and in vivo. A minor increase in the Aβ(42):Aβ(40) ratio stabilizes toxic oligomeric species with intermediate conformations. The initial toxic impact of these Aβ species is synaptic in nature, but this can spread into the cells leading to neuronal cell death. The fact that the relative ratio of Aβ peptides is more crucial than the absolute amounts of peptides for the induction of neurotoxic conformations has important implications for anti-amyloid therapy. Our work also suggests the dynamic nature of the equilibrium between toxic and non-toxic intermediates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The increased Aβ 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ40 is present in larger amounts in the brain, yet Aβ42 is more neurotoxic and has a higher tendency to aggregate.8–11”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the longer and more hydrophobic Aβ42 isoform has a higher tendency to generate neurotoxic oligomeric species.9,10”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although Aβ40 is present in larger amounts in the brain, Aβ42 was found to be more neurotoxic and have a higher tendency to aggregate.4,5”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Although it was shown in previous studies9,10,21 that the Aβ42 peptide is more prone to form neurotoxic soluble Aβ oligomers than the Aβ40 peptide”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…potently disrupt synaptic plasticity (Klyubin et al, 2008; Shankar et al, 2008), an Ab species of 56 kDa has been found neurotoxic in Tg2576 mice (Lesne et al, 2006), lipid-induced oligomers from mature fibrils (Martins et al, 2008), ADDLs (Lambert et al, 1998; Gong et al, 2003; Lacor et al,…”
BackgroundRetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Cited by
Sorted by citations
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Self-citationThe Amyloid State of Proteins in Human Diseases
Eisenberg, D. S., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,769
Compromised MAPK signaling in human diseases: an update
Kim, E., & Choi, E. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1472-2 · Cited by 1,033
Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques
Condello, C., Yuan, P., Schain, A., & Grutzendler, J. (2015) · Nature Communications · doi:10.1038/ncomms7176 · Cited by 718
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domínguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 680
Amyloid β Protein and Alzheimer’s Disease: When Computer Simulations Complement Experimental Studies
Nasica-Labouze, J., Nguyen, P. H., Sterpone, F., Berthoumieu, O., Buchete, N., Côté, S., Simone, A. D., Doig, A. J., Faller, P., García, A. E., et al. (2015) · Chemical Reviews · doi:10.1021/cr500638n · Cited by 591
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Self-citationNixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400
Role of Metal Ions in the Self-assembly of the Alzheimer’s Amyloid-β Peptide
Faller, P., Hureau, C., & Berthoumieu, O. (2013) · Inorganic Chemistry · doi:10.1021/ic4003059 · Cited by 360
Williams, T. L., & Serpell, L. C. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08228.x · Cited by 335
Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils
Gu, L., & Guo, Z. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12202 · Cited by 346
Stem-cell-derived human microglia transplanted in mouse brain to study human disease
Mancuso, R., Van Den Daele, J., Fattorelli, N., Wolfs, L., Balusu, S., Burton, O., Liston, A., Sierksma, A., Fourne, Y., Poovathingal, S., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0525-x · Cited by 295
Zempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., & Mandelkow, E. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.207 · Cited by 283
Sannerud, R., Esselens, C., Ejsmont, P., Mattera, R., Rochin, L., Tharkeshwar, A. K., De Baets, G., De Wever, V., Habets, R., Baert, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.020 · Cited by 299
Self-citationLessons from a failed γ-secretase Alzheimer trial
De Strooper, B. (2014) · Cell · doi:10.1016/j.cell.2014.10.016 · Cited by 277
Amyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276
Song, M., Jin, J., Lim, J.-E., Kou, J., Pattanayak, A., Rehman, J. A., Kim, H.-D., Tahara, K., Lalonde, R., & Fukuchi, K.-I. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-92 · Cited by 273
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 275
Structural Basis for Increased Toxicity of Pathological Aβ42:Aβ40 Ratios in Alzheimer Disease
Pauwels, K., Williams, T. L., Morris, K. L., Jonckheere, W., Vandersteen, A., Kelly, G., Schymkowitz, J., Rousseau, F., Pastore, A., Serpell, L. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.264473 · Cited by 253
Self-citationTargeting the neural extracellular matrix in neurological disorders
Soleman, S., Filippov, M. A., Dityatev, A., & Fawcett, J. W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.050 · Cited by 244
Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236
Lichtenthaler, S. F., Haass, C., & Steiner, H. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07248.x · Cited by 205
A review on advances of treatment modalities for Alzheimer's disease
Thoe, E. S., Fauzi, A., Tang, Y.-Q., Chamyuang, S., & Chia, A. Y. Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119129 · Cited by 234
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Ion Channel Formation by Amyloid-β42 Oligomers but Not Amyloid-β40 in Cellular Membranes
Bode, D. C., Baker, M. D., & Viles, J. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762526 · Cited by 210
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204
Self-citationMitani, Y., Yarimizu, J., Saita, K., Uchino, H., Akashiba, H., Shitaka, Y., Ni, K., & Matsuoka, N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4264-11.2012 · Cited by 203
Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide
Sharma, A. K., Pavlova, S. T., Kim, J., Finkelstein, D., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210588m · Cited by 202
Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease
Sun, D., Li, N., Zhang, W., Zhao, Z., Mou, Z., Huang, D., Liu, J., & Wang, W. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.08.052 · Cited by 202
Walgrave, H., Balusu, S., Snoeck, S., Vanden Eynden, E., Craessaerts, K., Thrupp, N., Wolfs, L., Horré, K., Fourne, Y., Ronisz, A., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.05.001 · Cited by 175
Self-citationAmyloid-based nanosensors and nanodevices
Hauser, C. A. E., Maurer‐Stroh, S., & Martins, I. C. (2014) · Chemical Society Reviews · doi:10.1039/c4cs00082j · Cited by 187
Self-citationA β 42 and A β 40: similarities and differences
Qiu, T., Liu, Q., Chen, Y., Zhao, Y., & Li, Y. (2015) · Journal of Peptide Science · doi:10.1002/psc.2789 · Cited by 180
Amyloid β Oligomers Disrupt Blood–CSF Barrier Integrity by Activating Matrix Metalloproteinases
Brkić, M., Balusu, S., Wonterghem, E. V., Gorlé, N., Benilova, I., Kremer, A., Hove, I. V., Moons, L., Strooper, B. D., Kanazir, S., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0006-15.2015 · Cited by 192
Self-citationHureau, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.037 · Cited by 183
Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates
Ilie, I. M., & Caflisch, A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00731 · Cited by 181
Brouillette, J., Caillierez, R., Zommer, N., Pires, C. A., Benilova, I., Blum, D. L., Strooper, B. D., & Buée, L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5901-11.2012 · Cited by 186
Self-citationSalivary biomarkers for the diagnosis and monitoring of neurological diseases
Farah, R., Haraty, H., Salame, Z., Fares, Y., Ojcius, D. M., & Sadier, N. S. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.03.004 · Cited by 175
A multi-pronged human microglia response to Alzheimer’s disease Aβ pathology
Mancuso, R., Fattorelli, N., Martinez-Muriana, A., Davis, E., Wolfs, L., Van Den Daele, J., Geric, I., Preman, P., Serneels, L., Poovathingal, S., et al. (2022) · doi:10.1101/2022.07.07.499139 · Cited by 169
Recent progress in understanding Alzheimer's β-amyloid structures
Fändrich, M., Schmidt, M., & Grigorieff, N. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.02.002 · Cited by 168
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F. G., Vaz, K., Nwokocha, C. R., Wilson-Clarke, C. F., Anderson, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 169
The physiology of the β‐amyloid precursor protein intracellular domain AICD
Pardossi‐Piquard, R., & Checler, F. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07475.x · Cited by 159
Fasae, K. D., Abolaji, A. O., Faloye, T. R., Odunsi, A., Oyetayo, B. O., Enya, J. I., Rotimi, J. A., Akinyemi, R., Whitworth, A. J., & Aschner, M. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126779 · Cited by 161
Faraco, G., Park, L., Zhou, P., Luo, W., Paul, S. M., Anrather, J., & Iadecola, C. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.79 · Cited by 158
A Hexameric Peptide Barrel as Building Block of Amyloid‐β Protofibrils
Lendel, C., Bjerring, M., Dubnovitsky, A. P., Kelly, R. T., Filippov, A. V., Antzutkin, O. N., Nielsen, N. C., & Härd, T. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201406357 · Cited by 160
Oxidative stress and lipid peroxidation are upstream of amyloid pathology
Arimon, M., Takeda, S., Post, K. E., Svirsky, S. E., Hyman, B. T., & Berezovska, O. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.013 · Cited by 157
Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease
Szaruga, M., Veugelen, S., Benurwar, M., Lismont, S., Sepulveda-Falla, D., Lleo, A., Ryan, N. S., Lashley, T., Fox, N. C., Murayama, S., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150892 · Cited by 155
Jeong, J. S., Ansaloni, A., Mezzenga, R., Lashuel, H. A., & Dietler, G. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.005 · Cited by 152
A Molecular History of the Amyloidoses
Buxbaum, J. N., & LINKE, R. P. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.024 · Cited by 157
Taurine and central nervous system disorders
Menzie, J., Pan, C., Prentice, H. M., & Wu, J. (2012) · Amino Acids · doi:10.1007/s00726-012-1382-z · Cited by 153
Domert, J., Rao, S. B., Agholme, L., Brorsson, A., Marcusson, J. O., Hallbeck, M., & Nath, S. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.12.019 · Cited by 156
Zhang, X., Liu, S., Song, X., Wang, H., Wang, J., Wang, Y., Huang, J., & Yu, J. (2019) · ACS Sensors · doi:10.1021/acssensors.9b00974 · Cited by 149
Benilova, I., Gallardo, R. U., Ungureanu, A.-A., Cano, V. C., Snellinx, A., Ramakers, M., Bartic, C., Rousseau, F., Schymkowitz, J. W. H., & Strooper, B. D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599027 · Cited by 151
Self-citationSchützmann, M. P., Hasecke, F., Bachmann, S., Zielinski, M., Hänsch, S., Schroeder, G. F., Zempel, H., & Hoyer, W. (2021) · Nature Communications · doi:10.1038/s41467-021-24900-4 · Cited by 152
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 144
Gamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
Bursavich, M. G., Harrison, B. A., & Blain, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01960 · Cited by 144
Seeded strain‐like transmission of β‐amyloid morphotypes in APP transgenic mice
Heilbronner, G., Eisele, Y. S., Langer, F., Kaeser, S. A., Novotny, R., Nagarathinam, A., Åslund, A., Hammarström, P., Nilsson, K. P. R., & Jucker, M. (2013) · EMBO Reports · doi:10.1038/embor.2013.137 · Cited by 143
Zempel, H., Dennissen, F. J. A., Kumar, Y., Luedtke, J., Biernat, J., Mandelkow, E., & Mandelkow�, E. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784702 · Cited by 147
Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer’s disease.
Inestrosa, N., & Tapia-Rojas, C. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238606 · Cited by 137
Fernandez, M. A., Klutkowski, J. A., Freret, T., & Wolfe, M. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.581165 · Cited by 136
The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity
Sharma, A. K., Pavlova, S. T., Kim, J., Kim, J., & Mirica, L. M. (2013) · Metallomics · doi:10.1039/c3mt00161j · Cited by 135
Biometals and Their Therapeutic Implications in Alzheimer's Disease
Ayton, S., Lei, P., & Bush, A. I. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0312-z · Cited by 134
Synaptic dysfunction and septin protein family members in neurodegenerative diseases
Marttinen, M., Kurkinen, K. M. A., Soininen, H. S., Haapasalo, A., & Hiltunen, M. O. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0013-z · Cited by 138
Eitan, E., Hutchison, E. R., Marosi, K., Comotto, J., Mustapic, M., Nigam, S. M., Suire, C., Maharana, C., Jicha, G. A., Liu, D., et al. (2016) · npj Aging and Mechanisms of Disease · doi:10.1038/npjamd.2016.19 · Cited by 129
Nirmalraj, P. N., List, J., Battacharya, S., Howe, G., Xu, L., Thompson, D., & Mayer, M. (2020) · Science Advances · doi:10.1126/sciadv.aaz6014 · Cited by 131
The role of amyloid oligomers in neurodegenerative pathologies
Wells, C., Brennan, S. E., Keon, M., & Ooi, L. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.113 · Cited by 131
Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T. S., Mori, K., Nakayama, T., Ihara, Y., & Takeda, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.028 · Cited by 123
Broersen, K., Jonckheere, W., Rozenski, J., Vandersteen, A., Pauwels, K., Pastore, A., Rousseau, F., & Schymkowitz, J. W. H. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzr020 · Cited by 129
Self-citationAlzheimer's Disease and the Amyloid β-Protein
Walsh, D. M., & Teplow, D. B. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00012-6 · Cited by 121
Aso, E., Lomoio, S., López‐González, I., Joda, L., Carmona, M., Fernández‐Yagüe, N., Moreno, J., Juvés, S., Pujol, A., Pamplona, R., et al. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00560.x · Cited by 118
Quintero-Monzon, O., Martin, M. M., Fernandez, M. A., Cappello, C. A., Krzysiak, A. J., Osenkowski, P., & Wolfe, M. S. (2011) · Biochemistry · doi:10.1021/bi2007146 · Cited by 118
Sangwan, S., Zhao, A., Adams, K. L., Jayson, C. K., Sawaya, M. R., Guenther, E. L., Pan, A. C., Ngo, J., Moore, D. M., Soriaga, A. B., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705091114 · Cited by 118
Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys, J., Valverde, A., & Checler, F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003999 · Cited by 120
Rana, M., & Sharma, A. K. (2018) · Metallomics · doi:10.1039/c8mt00203g · Cited by 116
Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111
Ai, J., Sun, L., Che, H., Zhang, R., Zhang, T.-Z., Wu, W.-C., Su, X., Chen, X., Yang, G., Li, K., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1997-12.2013 · Cited by 109
Deng, Y., Wang, Z., Wang, R., Zhang, X., Zhang, S., Wu, Y., Staufenbiel, M., Cai, F., & Song, W. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12235 · Cited by 108
Determinants of amyloid fibril degradation by the PDZ protease HTRA1
Poepsel, S., Sprengel, A., Saccà, B., Kaschani, F., Kaiser, M., Gatsogiannis, C., Raunser, S., Clausen, T., & Ehrmann, M. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1931 · Cited by 110
The role of amyloid β in the pathogenesis of Alzheimer's disease
Gilbert, B. J. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201515 · Cited by 109
Central Angiotensin II Stimulation Promotes β Amyloid Production in Sprague Dawley Rats
Zhu, D., Shi, J., Zhang, Y., Wang, B., Liu, W., Chen, Z., & Tong, Q. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016037 · Cited by 112
Alexandru, A., Jagla, W., Graubner, S., Becker, A., Bäuscher, C., Kohlmann, S., Sedlmeier, R., Raber, K. A., Cynis, H., Rönicke, R., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1794-11.2011 · Cited by 102
Chebaro, Y., Jiang, P., Zang, T., Mu, Y., Nguyen, P. H., Mousseau, N., & Derreumaux, P. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp2118778 · Cited by 102
Transient dynamics of Aβ contribute to toxicity in Alzheimer’s disease
Hubin, E., van Nuland, N. A. J., Broersen, K., & Pauwels, K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1634-z · Cited by 102
Self-citationAlzheimer’s disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory
Klyubin, I. V., Cullen, W. K., Hu, N., & Rowan, M. J. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-25 · Cited by 105
Faucher, P., Mons, N., Micheau, J., Louis, C., & Beracochea, D. J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00245 · Cited by 100
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Moreth, J., Mavoungou, C., & Schindowski, K. (2013) · Immunity & Ageing · doi:10.1186/1742-4933-10-18 · Cited by 103
Ryan, P., Patel, B., Makwana, V., Jadhav, H. R., Kiefel, M. J., Davey, A. K., Reekie, T. A., Rudrawar, S., & Kassiou, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00185 · Cited by 101
Notarachille, G., Arnesano, F., Calò, V., & Meleleo, D. (2014) · BioMetals · doi:10.1007/s10534-014-9719-6 · Cited by 97
Lima, M. G. P., Schimidt, H. L., Garcia, A., Daré, L. R., Carpes, F. P., Izquierdo, I., & Mello‐Carpes, P. B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718435115 · Cited by 95
Pavoni, S., Jarray, R., Nassor, F., Guyot, A.-C., Cottin, S., Rontard, J., Mikol, J., Mabondzo, A., Deslys, J.-P., & Yates, F. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209150 · Cited by 97
Pomeshchik, Y., Klementieva, O., Gil, J., Martinsson, I., Hansen, M. G., de Vries, T., Sancho-Balsells, A., Russ, K., Savchenko, E., Collin, A., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.06.001 · Cited by 95
Amadoro, G., Corsetti, V., Atlante, A., Florenzano, F., Capsoni, S., Bussani, R., Mercanti, D., & Calissano, P. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.001 · Cited by 95
Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer’s Drug Discovery
Bu, X., Rao, P. P. N., & Wang, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9301-4 · Cited by 97
He, Y., Cui, J., Lee, J. C., Ding, S., Chalimoniuk, M., Simonyi, Á., Sun, A. Y., Gu, Z., Weisman, G. A., Wood, W. G., et al. (2011) · ASN NEURO · doi:10.1042/an20100025 · Cited by 95
Age-related diseases as vicious cycles
Belikov, A. V. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.002 · Cited by 95
Shih, Y., Tu, L., Chang, T.-Y., Ganesan, K., Chang, W.-W., Chang, P.-S., Fang, Y.-S., Lin, Y.-T., Jin, L., & Chen, Y. (2020) · Nature Communications · doi:10.1038/s41467-020-19786-7 · Cited by 92
Metadata
- Authors
- Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., Braeken, D., Callewaert, G., Bartic, C., D'Hooge, R., Martins, I. C., Rousseau, F., Schymkowitz, J., & De Strooper, B.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Vrije Universiteit Brussel (BE)
- Rega Institute for Medical Research (BE)
- University of Twente (NL)
- IMEC (BE)
- Corresponding author
- Schymkowitz, Joost
- ORCID
- Venue
- The EMBO Journal
- Published
- 2010-09-03
- Volume
- 29
- Issue
- 19
- Pages
- 3408-3420
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC2957213
- OpenAlex
- W1966694507
- Cited by
- 532
- References
- 61
- Citations by year
- 2026: 16 · 2025: 23 · 2024: 36 · 2023: 39 · 2022: 27 · 2021: 39 · 2020: 32 · 2019: 33 · 2018: 31 · 2017: 35 · 2016: 48 · 2015: 31 · 2014: 30 · 2013: 42 · 2012: 43
- FWCI
- 24.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The EMBO Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- University of Twente Research Information (publishedVersion, other-oa)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- University of Twente Research Information (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- European Commission (200611)
- Fonds Wetenschappelijk Onderzoek (P6/43)
- Vlaamse regering
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, Aβ42/Aβ40 ratio, neurotoxicity, oligomeric intermediates, fibril morphology, synaptic dysfunction, neuronal cell death, anti-amyloid therapy, peptide mixtures
- MeSH terms
- Alzheimer Disease, Analysis of Variance, Animals, Biophysics, Fluorescent Dyes, Humans, Kinetics, Microelectrodes, Neurons, Peptide Fragments, Protein Binding, Thiazoles, Amyloid beta-Peptides, Spectroscopy, Fourier Transform Infrared, Patch-Clamp Techniques, Microscopy, Electron, Transmission, Mice, Benzothiazoles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
